NCT00071838View on ClinicalTrials.gov

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 30, 2003

Primary Completion Date

October 4, 2007

Study Completion Date

August 16, 2011

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Daclizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00071838 - Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter